CLEC12A has raised interest as a therapeutic target not only because this glycoprotein is widely expressed on AML blasts at diagnosis and throughout the treatment course, but also because it is displayed on putative AML stem/progenitor cells [83,84]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.